TB-500
A synthetic thymosin β4 fragment marketed for recovery; preclinical evidence.
Identity
- Class
- Synthetic thymosin β4 fragment / analog
- Source
- Synthetic; based on thymosin β4
- Receptor
- Same actin-related biology as thymosin β4 (not receptor-mediated)
Mechanism
TB-500 is a synthetic product based on thymosin β4 — often a specific active fragment — promoted for recovery and healing. Its rationale borrows from thymosin β4's actin and angiogenesis biology, but human clinical evidence specific to TB-500 is limited and preclinical.
Reference notes
- TB-500 is derived from thymosin β4 but is not identical to the full endogenous peptide.
- Its claims lean on thymosin β4 biology; direct human evidence for TB-500 is limited.
- It is a 'research peptide' product — read the evidence honestly.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance · Sports medicine (Auckland, N.Z.), 2026 · PMID 41966639
- 2.Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians · The American journal of sports medicine, 2026 · PMID 41476424